Tradewinds Capital Management’s BioLineRX BLRX Stock Holding History

Tradewinds Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5	Closed	-$43	–	672
2024 Q4	$43	Hold	5	–	–	﹤0.01%	658
2024 Q3	$108	Hold	5	–	–	﹤0.01%	596
2024 Q2	$114	Hold	5	–	–	﹤0.01%	568
2024 Q1	$224	Hold	5	–	–	﹤0.01%	520
2023 Q4	$314	Hold	5	–	–	﹤0.01%	430
2023 Q3	$364	Buy	+5	New	+$336	﹤0.01%	445

Other funds holding BLRX

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tradewinds Capital Management's BLRX Position: Q1 2025 in Review

Tradewinds Capital Management sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 5 shares — an estimated $43 sold.

Tradewinds Capital Management first reported a position in BLRX in Q3 2023 and held it in 6 quarters. The position peaked at $364 in Q3 2023. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

Tradewinds Capital Management reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
Tradewinds Capital Management sold 5 BioLineRX shares in Q1 2025, an estimated $43.
Tradewinds Capital Management first reported a position in BioLineRX in Q3 2023 and held it in 6 quarters.
Tradewinds Capital Management's BioLineRX position peaked at $364 in Q3 2023.
12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Tradewinds Capital Management's 13F filing for Q1 2025, filed 25 Apr 2025.